Respiratory

Chronic Rhinosinusitis

GlycoMira is developing an effective treatment for chronic rhinosinusitis, a debilitating inflammatory disease that substantially diminishes the quality of life and productivity of up to 16% of the U.S. population and requires $64B annually in direct costs to treat patients. Currently available therapies fail to help 20% of patients, underscoring the dire need for new therapeutics that can improve the lives of millions of Americans.